Perspectives by the Leerink Center for Pharmacoeconomics
Perspectives by the Leerink Center for Pharmacoeconomics
Podcast Description
Welcome to Perspectives, a signature podcast series from the Leerink Center for Pharmacoeconomics. Hosted by Dr. Mel Whittington, a health economist and Head of the Center for Pharmacoeconomics, we will be hearing from individuals across the industry to better understand and appreciate the societal impact of healthcare innovations.
Podcast Insights
Content Themes
The podcast focuses on healthcare innovations, cost-effectiveness analysis, and the societal impact of health policies, with episodes including discussions on Generalized Cost Effectiveness Analysis (GCEA) and communication strategies for health impacts. Specific themes also cover the intersection of health journalism and economics.
Welcome to Perspectives, a signature podcast series from the Leerink Center for Pharmacoeconomics. Hosted by Dr. Mel Whittington, a health economist and Head of the Center for Pharmacoeconomics, we will be hearing from individuals across the industry to better understand and appreciate the societal impact of healthcare innovations.
Rob Abbott, CEO of ISPOR, joins Perspectives to talk about why health economics and outcomes research (HEOR) has become more relevant for biotech founders, executives, and investors. The conversation challenges the common perception that HEOR is primarily a post-approval exercise used to support pricing and reimbursement. Instead, Rob discusses how evidence generation, economic modeling, and value strategy can shape clinical development, inform investment decisions, and strengthen the commercial potential of new therapies. The episode concludes with a discussion of ISPOR’s Healthcare Investment Summit that will be held in September 2026 and will convene investors, drug developers, and value strategists to translate HEOR into early-stage investment decisions and drug development.
Topics discussed include:
- Two HEOR activities biotech companies should do before Phase III
- Four questions investors can ask management teams to gauge commercial opportunity
- Novel applications of HEOR and their usefulness for biotech executives and investors
- ISPOR’s Healthcare Investment Summit and what biotech leaders and investors might get out of attending
Disclaimer
This podcast’s information is provided for general reference and was obtained from publicly accessible sources. The Podcast Collaborative neither produces nor verifies the content, accuracy, or suitability of this podcast. Views and opinions belong solely to the podcast creators and guests.
For a complete disclaimer, please see our Full Disclaimer on the archive page. The Podcast Collaborative bears no responsibility for the podcast’s themes, language, or overall content. Listener discretion is advised. Read our Terms of Use and Privacy Policy for more details.